Cheap Broker Fees
Vir Biotechnology Inc is a biotechnology business based in the US. Vir Biotechnology shares (VIR) are listed on the NASDAQ and all prices are listed in US Dollars. Vir Biotechnology employs 367 staff and has a trailing 12-month revenue of around USD$182.7 million.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Since the stock market crash in March caused by coronavirus, Vir Biotechnology's stock price has had significant positive movement.
Its last market close was $39.09, which is 58.40% up on its pre-crash value of $16.26 and 142.95% up on the lowest point reached during the March crash when the stocks fell as low as $16.09.
If you had bought $1,000 worth of Vir Biotechnology stocks at the start of February 2020, those stocks would have been worth $1,605.35 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,714.10.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||$39.09|
|52-week range||$25.31 - $83.50|
|50-day moving average||$45.21|
|200-day moving average||$43.92|
|Wall St. target price||$68.14|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.33|
|1 week (2021-10-11)||-2.32%|
|1 month (2021-09-17)||-28.33%|
|3 months (2021-07-17)||-5.37%|
|6 months (2021-04-16)||-15.72%|
|1 year (2020-10-16)||-0.89%|
|2 years (2019-10-18)||186.16%|
|3 years (2018-10-14)||N/A|
|5 years (2016-10-14)||N/A|
|Revenue TTM||$182.7 million|
|Gross profit TTM||$-196,511,000|
|Return on assets TTM||-18.69%|
|Return on equity TTM||-45.71%|
|Market capitalisation||$5.1 billion|
TTM: trailing 12 months
There are currently 5.2 million Vir Biotechnology shares held short by investors – that's known as Vir Biotechnology's "short interest". This figure is 8.1% down from 5.7 million last month.
There are a few different ways that this level of interest in shorting Vir Biotechnology shares can be evaluated.
Vir Biotechnology's "short interest ratio" (SIR) is the quantity of Vir Biotechnology shares currently shorted divided by the average quantity of Vir Biotechnology shares traded daily (recently around 858538.7888707). Vir Biotechnology's SIR currently stands at 6.11. In other words for every 100,000 Vir Biotechnology shares traded daily on the market, roughly 6110 shares are currently held short.
However Vir Biotechnology's short interest can also be evaluated against the total number of Vir Biotechnology shares, or, against the total number of tradable Vir Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vir Biotechnology's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Vir Biotechnology shares in existence, roughly 40 shares are currently held short) or 0.0744% of the tradable shares (for every 100,000 tradable Vir Biotechnology shares, roughly 74 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Vir Biotechnology.
We're not expecting Vir Biotechnology to pay a dividend over the next 12 months.
Over the last 12 months, Vir Biotechnology's shares have ranged in value from as little as $25.31 up to $83.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vir Biotechnology's is -1.314. This would suggest that Vir Biotechnology's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Vir Biotechnology has bucked the trend.
Vir Biotechnology, Inc. , a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. ; a collaboration, license, and option agreement with Visterra, Inc. ; license agreements with The Rockefeller University and MedImmune, Inc. ; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.
What you need to know about investing in Bucket Studio from Singapore.
Learn how to stake AVAX tokens and earn rewards by supporting the Avalanche blockchain.
True to its name, SuperRare is an NFT marketplace that focuses on crypto art tokenised on the Ethereum blockchain. The result is part marketplace and part social network for the artistic side of the NFT community.
Find out how a Web 3.0 wallet can allow you to access the world of DeFi, plus discover which wallets we recommend.
What you need to know about investing in Evergrande from Singapore.
Buy and sell unique digital assets on the largest NFT marketplace in the crypto space.
Find out how to stake your THETA tokens and how Theta’s multi-BFT proof-of-stake consensus mechanism works.
This guide will show you step-by-step instructions on how to buy the Quickswap (QUICK) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the DexTools (DEXT) token as well as a list of exchanges you can trade it on.
DeFi tokens compose a prominent sector in the cryptocurrency markets. Learn the basics of these tokens here.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.